Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720713 | 0.82 | SLC6A4 (0.61) | SLC6A4HRH3ROCK1 | |
| SCHEMBL4722875 | 0.74 | SLC6A4 (1.00) | SLC6A4HRH3 | |
| SCHEMBL4721634 | 0.73 | SLC6A4 (1.00) | SLC6A4HRH3 | |
| SCHEMBL4721767 | 0.73 | SLC6A4 (0.71) | SLC6A4HRH3 | |
| SCHEMBL4720682 | 0.73 | SLC6A4 (1.00) | SLC6A4HRH3 | |
| SCHEMBL4723286 | 0.71 | SLC6A4 (0.80) | SLC6A4HRH3 | |
| SCHEMBL4720940 | 0.71 | SLC6A4 (0.65) | SLC6A4HRH3 | |
| SCHEMBL4722356 | 0.70 | SLC6A4 (1.00) | SLC6A4HRH3 | |
| SCHEMBL28172286 | 0.68 | SIGMAR1 (0.69) | SIGMAR1MEN1KMT2A | |
| SCHEMBL4721189 | 0.68 | SLC6A4 (1.00) | SLC6A4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899334-B1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | claimed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | claimed |
| EP-1899334-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | claimed |
| WO-2006138714-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | claimed |
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | claimed |
| EP-1899334-B1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1899334-B1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| EP-1899334-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006138714-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | HRH3, HRH4, HRH1 | SLC6A4 10/4885HRH3 1/4885ROCK1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.